CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Trade PDS Biotechnology Corporation - PDSB CFD

8.52
27.16%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.025457 %
Charges from borrowed part ($-1.02)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.025457%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003235 %
Charges from borrowed part ($0.13)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
0.003235%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

PDS Biotechnology Corp ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 6.7
Open* 7.94
1-Year Change* 58.17%
Day's Range* 7.42 - 8.85
52 wk Range 2.89-13.65
Average Volume (10 days) 800.79K
Average Volume (3 months) 8.83M
Market Cap 263.85M
P/E Ratio -100.00K
Shares Outstanding 30.82M
Revenue N/A
EPS -1.44
Dividend (Yield %) N/A
Beta 2.10
Next Earnings Date Aug 7, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
May 26, 2023 8.52 0.56 7.04% 7.96 8.89 7.29
May 25, 2023 6.70 -0.40 -5.63% 7.10 7.10 6.60
May 24, 2023 7.19 -0.30 -4.01% 7.49 7.53 7.03
May 23, 2023 7.62 -0.25 -3.18% 7.87 8.16 7.62
May 22, 2023 7.84 0.26 3.43% 7.58 8.01 7.53
May 19, 2023 7.37 -0.11 -1.47% 7.48 7.81 7.21
May 18, 2023 7.36 0.28 3.95% 7.08 7.80 7.04
May 17, 2023 7.02 0.04 0.57% 6.98 7.22 6.78
May 16, 2023 6.73 -0.10 -1.46% 6.83 6.96 6.55
May 15, 2023 6.91 0.54 8.48% 6.37 7.15 6.37
May 12, 2023 6.40 -0.28 -4.19% 6.68 6.68 6.30
May 11, 2023 6.67 -0.13 -1.91% 6.80 6.80 6.48
May 10, 2023 6.79 -0.11 -1.59% 6.90 7.04 6.61
May 9, 2023 6.85 0.22 3.32% 6.63 6.94 6.48
May 8, 2023 6.71 0.32 5.01% 6.39 6.77 6.38
May 5, 2023 6.48 0.30 4.85% 6.18 6.55 6.17
May 4, 2023 6.23 0.06 0.97% 6.17 6.30 6.14
May 3, 2023 6.25 0.37 6.29% 5.88 6.32 5.84
May 2, 2023 5.88 -0.15 -2.49% 6.03 6.04 5.83
May 1, 2023 6.07 -0.01 -0.16% 6.08 6.27 5.93

PDS Biotechnology Corporation Events

Time (UTC) Country Event
Tuesday, June 6, 2023

Time (UTC)

12:00

Country

US

Event

PDS Biotechnology Corp To Host Post ASCO Call
PDS Biotechnology Corp To Host Post ASCO Call

Forecast

-

Previous

-
Thursday, June 15, 2023

Time (UTC)

13:00

Country

US

Event

PDS Biotechnology Corp Annual Shareholders Meeting
PDS Biotechnology Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, August 7, 2023

Time (UTC)

12:30

Country

US

Event

Q2 2023 PDS Biotechnology Corp Earnings Release
Q2 2023 PDS Biotechnology Corp Earnings Release

Forecast

-

Previous

-
Monday, November 13, 2023

Time (UTC)

13:30

Country

US

Event

Q3 2023 PDS Biotechnology Corp Earnings Release
Q3 2023 PDS Biotechnology Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Revenue 0
Total Operating Expense 41.6724 21.4393 14.9024 7.70005 43.0966
Selling/General/Admin. Expenses, Total 12.2414 10.1848 6.96233 8.91149 15.0205
Research & Development 29.431 11.2545 7.92445 6.09958 16.0688
Operating Income -41.6724 -21.4393 -14.9024 -7.70005 -43.0966
Interest Income (Expense), Net Non-Operating -0.38134 0.00435 0.05501 0.31993 -0.55338
Other, Net 0 0
Net Income Before Taxes -42.0538 -21.435 -14.8474 -7.38012 -43.6499
Net Income After Taxes -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income Before Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Income Available to Common Incl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Diluted Weighted Average Shares 28.5992 25.5971 16.745 4.86808 1.56211
Diluted EPS Excluding Extraordinary Items -1.42853 -0.66095 -0.88667 -1.43765 -26.1621
Diluted Normalized EPS -1.42853 -0.66095 -0.85692 -2.41384 -21.1658
Total Extraordinary Items 0
Unusual Expense (Income) 0 -7.31102 12.0073
Depreciation / Amortization 0.01561 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 9.42241 18.8214 7.2792 7.09265 8.47922
Selling/General/Admin. Expenses, Total 3.57873 2.66627 2.92621 3.33101 3.31791
Research & Development 5.84369 16.1551 4.35299 3.76165 5.16132
Operating Income -9.42241 -18.8214 -7.2792 -7.09265 -8.47922
Interest Income (Expense), Net Non-Operating -0.23751 -0.14525 0.07455 0.0057
Net Income Before Taxes -9.65992 -19.1377 -7.42445 -7.01811 -8.47352
Net Income After Taxes -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Net Income Before Extra. Items -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Net Income -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Income Available to Common Excl. Extra. Items -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Income Available to Common Incl. Extra. Items -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Diluted Net Income -9.65992 -19.1377 -7.42445 -5.8192 -8.47352
Diluted Weighted Average Shares 30.428 29.0379 28.4587 28.4516 26.1612
Diluted EPS Excluding Extraordinary Items -0.31747 -0.65906 -0.26089 -0.20453 -0.3239
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.31747 -0.65906 -0.26089 -0.20453 -0.3239
Other, Net -0.31633
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 76.4804 66.8402 30.3372 14.4702 35.6511
Cash and Short Term Investments 73.8202 65.2426 28.8396 12.1617 34.6455
Cash & Equivalents 73.8202 65.2426 28.8396 12.1617 34.6455
Prepaid Expenses 2.66023 1.59757 1.49767 2.30846 1.00559
Total Assets 77.0079 67.1979 30.8904 14.4913 36.221
Property/Plant/Equipment, Total - Net 0.52753 0.3577 0.55315 0.02105 0.42695
Property/Plant/Equipment, Total - Gross 0.64295 0.47303 0.66313 0.11542 0.87862
Accumulated Depreciation, Total -0.11542 -0.11533 -0.10998 -0.09437 -0.45166
Other Long Term Assets, Total 0 0.14287
Total Current Liabilities 9.82104 3.75603 3.27045 2.79355 6.38175
Accounts Payable 1.21929 1.3094 1.41522 1.19772 0.39945
Accrued Expenses 8.54514 2.44663 1.85523 1.09764 0.38616
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.05661 0
Other Current Liabilities, Total 0 0.49819 5.59614
Total Liabilities 33.0059 3.98746 3.7608 2.79355 6.38175
Total Long Term Debt 23.1849 0 0 0 0
Long Term Debt 23.0208 0 0
Total Equity 44.002 63.2104 27.1296 11.6977 29.8392
Common Stock 0.00996 0.00939 0.00735 0.00174 0.01059
Additional Paid-In Capital 145.55 123.905 70.9073 40.6337 222.645
Retained Earnings (Accumulated Deficit) -101.558 -60.7036 -43.7851 -28.9377 -192.816
Total Liabilities & Shareholders’ Equity 77.0079 67.1979 30.8904 14.4913 36.221
Total Common Shares Outstanding 30.1703 28.4486 22.2616 5.28124 1.5725
Preferred Stock - Non Redeemable, Net 0
Other Liabilities, Total 0 0.23143 0.49035 0
Capital Lease Obligations 0.16401
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 67.9734 76.4804 74.4113 55.7426 60.7305
Cash and Short Term Investments 65.1994 73.8202 71.6424 52.9847 58.8811
Cash & Equivalents 65.1994 73.8202 71.6424 52.9847 58.8811
Prepaid Expenses 2.77399 2.66023 2.76891 2.75791 1.84941
Total Assets 68.4486 77.0079 74.8868 56.0008 61.0388
Property/Plant/Equipment, Total - Net 0.47526 0.52753 0.47542 0.25819 0.30833
Total Current Liabilities 4.12954 9.82104 4.84114 4.51592 5.01849
Accounts Payable 2.07206 1.21929 2.03739 1.87799 2.74571
Accrued Expenses 2.00537 8.54514 2.74248 2.63793 2.27278
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 27.4377 33.0059 27.8279 4.57557 5.16547
Total Long Term Debt 23.3081 23.1849 22.9868 0 0
Other Liabilities, Total 0 0 0.05965 0.14698
Total Equity 41.0109 44.002 47.0588 51.4252 55.8734
Common Stock 0.01014 0.00996 0.00939 0.00939 0.00939
Additional Paid-In Capital 152.219 145.55 129.47 126.412 125.041
Retained Earnings (Accumulated Deficit) -111.218 -101.558 -82.4207 -74.9963 -69.1771
Total Liabilities & Shareholders’ Equity 68.4486 77.0079 74.8868 56.0008 61.0388
Total Common Shares Outstanding 30.7236 30.1703 28.4587 28.4587 28.4509
Current Port. of LT Debt/Capital Leases 0.05211 0.05661 0.06127
Long Term Debt 23.1428 23.0208 22.9097
Capital Lease Obligations 0.16529 0.16401 0.07713
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -40.8549 -16.9185 -14.8474 -6.99861 -40.868
Cash From Operating Activities -25.7097 -12.4861 -13.1491 -18.0735 -33.1533
Cash From Operating Activities 0.04908 0.00536 0.01561 0.09841 0.17435
Non-Cash Items 10.6211 4.35124 0.61297 -6.22017 10.9689
Cash Interest Paid 0.85222 0 1.05117
Changes in Working Capital 4.47498 0.07582 1.06967 -4.5716 -3.4285
Cash From Investing Activities 0 29.3815 0
Capital Expenditures 0
Cash From Financing Activities 34.2872 48.8891 29.827 0.75 -20.2688
Financing Cash Flow Items -0.72029 -0.99
Issuance (Retirement) of Stock, Net 10.0075 48.8891 29.827 0.75 0.7212
Issuance (Retirement) of Debt, Net 25 0 -20
Net Change in Cash 8.57754 36.4031 16.6778 12.058 -53.4221
Deferred Taxes 0 -0.38151
Cash Taxes Paid 0
Other Investing Cash Flow Items, Total 0 29.3815
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -9.65992 -40.8549 -21.7172 -14.2927 -8.47352
Cash From Operating Activities -13.1886 -25.7097 -18.1808 -12.2879 -6.36901
Cash From Operating Activities 0.01411 0.04908 0.0375 0.00009 0.00009
Non-Cash Items 2.26257 10.6211 4.07542 2.59809 1.18923
Changes in Working Capital -5.8054 4.47498 -0.57652 -0.59332 0.9152
Cash From Financing Activities 4.56786 34.2872 24.5806 0.02992 0.00749
Issuance (Retirement) of Stock, Net 4.58852 10.0075 0.02992 0.02992 0.00749
Net Change in Cash -8.62078 8.57754 6.39982 -12.2579 -6.36152
Cash Interest Paid 0.96685 0.85222 0.0625
Financing Cash Flow Items -0.72029 -0.44933
Issuance (Retirement) of Debt, Net -0.02067 25 25
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.2126 1298475 136950 2023-03-31 LOW
Two Sigma Investments, LP Hedge Fund 3.807 1173450 117781 2023-03-31 HIGH
Bedu-Addo (Frank) Individual Investor 2.2414 690870 4 2023-03-31
Millennium Management LLC Hedge Fund 1.9345 596272 144936 2023-03-31 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.4755 454791 7750 2023-03-31 LOW
Sykes (Richard) Individual Investor 1.444 445108 0 2023-03-31
Renaissance Technologies LLC Hedge Fund 1.1865 365737 118400 2023-03-31 HIGH
EAM Investors, LLC Investment Advisor/Hedge Fund 1.072 330426 330426 2022-12-31 HIGH
LPL Financial LLC Investment Advisor 1.0649 328247 -50213 2023-03-31 LOW
Inspirion Wealth Advisors, LLC Investment Advisor 1.0209 314684 565 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9481 292253 12662 2023-03-31 LOW
First Manhattan Co. LLC Investment Advisor 0.8811 271576 0 2023-03-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.6978 215078 96915 2023-03-31 MED
Qube Research & Technologies Ltd Hedge Fund 0.6524 201083 201083 2023-03-31 HIGH
Cubist Systematic Strategies, LLC Hedge Fund 0.5305 163507 107197 2023-03-31 HIGH
D. E. Shaw & Co., L.P. Hedge Fund 0.5281 162769 -176909 2023-03-31 LOW
Sofinnova Investments, Inc Venture Capital 0.4627 142635 0 2023-03-31 MED
Marshall Wace LLP Investment Advisor/Hedge Fund 0.451 139008 103376 2023-03-31 HIGH
Citadel Advisors LLC Hedge Fund 0.4052 124907 97679 2023-03-31 HIGH
Jane Street Capital, L.L.C. Research Firm 0.4021 123936 92807 2023-03-31 HIGH

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group

530K+

Traders

87K+

Active clients monthly

$46M+

Monthly investing volume

$31M+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

PDS Biotechnology Corporation Company profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Industry: Bio Therapeutic Drugs

25B Vreeland Road
Suite 300
FLORHAM PARK
NEW JERSEY 07932
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

72.93 Price
+0.040% 1D Chg, %
Long position overnight fee -0.0146%
Short position overnight fee -0.0073%
Overnight fee time 21:00 (UTC)
Spread 0.03

BTC/USD

27,818.65 Price
+0.770% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

Gold

1,945.59 Price
-0.070% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0102%
Overnight fee time 21:00 (UTC)
Spread 0.30

US100

14,345.60 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0255%
Short position overnight fee 0.0032%
Overnight fee time 21:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading